首页 | 本学科首页   官方微博 | 高级检索  
     

桑枝总生物碱片联合达格列净治疗2型糖尿病的临床研究
引用本文:员富圆,刘龙飞,白慧敏. 桑枝总生物碱片联合达格列净治疗2型糖尿病的临床研究[J]. 现代药物与临床, 2023, 38(7): 1712-1716
作者姓名:员富圆  刘龙飞  白慧敏
作者单位:三门峡市中医院 内分泌科, 河南 三门峡 472000
基金项目:三门峡市科技发展计划项目(2020040344)
摘    要:目的 探讨桑枝总生物碱片联合达格列净片治疗2型糖尿病的临床疗效。方法 选取2020年4月1日—2021年12月31日三门峡市中医院收治的84例2型糖尿病患者,将所有患者按照随机数字表法分为对照组和治疗组,每组各42例。对照组每日早晨口服达格列净片,10 mg/次,1次/d。治疗组在对照组基础上口服桑枝总生物碱片,起始剂量1片/次,持续治疗4周后,剂量调整为2片/次,3次/d。两组患者连续治疗24周。考察两组临床疗效,比较两组的生活质量、血糖指标、氧化应激指标。结果 治疗后,治疗组患者的总有效率为95.24%,对照组的总有效率为80.95%,组间比较差异有统计学意义(P<0.05)。治疗后,两组的糖尿病生存质量特异性量表(DSQL)评分明显低于治疗前(P<0.05),且治疗组的DSQL评分明显低于对照组(P<0.05)。治疗后,两组的空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)均显著降低(P<0.05),且治疗组FPG、2 h PG、HbA1c明显低于对照组(P<0.05)。治疗后,两组的血清谷胱甘肽过氧化酶(GSH-Px)、总抗氧化能力(TAOC)水平高于治疗前,蛋白氧化终产物(AOPPs)水平低于治疗前(P<0.05);治疗组的血清GSH-Px、TAOC水平高于对照组,血清AOPPs水平低于对照组,组间差异具有统计学意义(P<0.05)。结论 桑枝总生物碱片联合达格列净片治疗2型糖尿病具有较好的临床疗效,能改善患者生活质量,显著降低血糖水平,降低氧化应激反应。

关 键 词:桑枝总生物碱片  达格列净片  2型糖尿病  糖尿病生存质量特异性量表评分  空腹血糖  餐后2 h血糖  糖化血红蛋白  谷胱甘肽过氧化酶  总抗氧化能力  蛋白氧化终产物
收稿时间:2023-01-05

Clinical study on Mulberry Twig Alkaloids Tablets combined with dapagliflozin in treatment of type 2 diabetes mellitus
YUAN Fu-yuan,LIU Long-fei,BAI Hui-min. Clinical study on Mulberry Twig Alkaloids Tablets combined with dapagliflozin in treatment of type 2 diabetes mellitus[J]. Drugs & Clinic, 2023, 38(7): 1712-1716
Authors:YUAN Fu-yuan  LIU Long-fei  BAI Hui-min
Affiliation:Department of Endocrinology, Sanmenxia Hospital of Traditional Chinese Medicine, Sanmenxia 472000, China
Abstract:Objective To investigate the clinical effect of Mulberry Twig Alkaloids Tablets combined with Dapagliflozin Tablets in treatment of type 2 diabetes mellitus. Methods Patients (84 cases) with type 2 diabetes mellitus in Sanmenxia Hospital of Traditional Chinese Medicine from April 1, 2020 to December 31, 2021 were divided into control and treatment groups according to the random number table method, and each group had 42 cases. Patients in the control group were po administered with Dapagliflozin Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Mulberry Twig Alkaloids Tablets on the basis of the control group, with the initial dose 1 tablet/time. After 4 weeks of continuous treatment, the dose was adjusted to 2 tablets/time, three times daily. Patients in two groups were treated for 24 weeks. After treatment, the clinical efficacies were evaluated, and quality of life, blood glucose indicators, and oxidative stress indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.24%, that of the control group was 80.95%, and the difference between two groups was statistically significant (P < 0.05). After treatment, DSQL scores of two groups were significantly lower than those before treatment (P < 0.05), and DSQL scores of the treatment group were significantly lower than those of the control group (P < 0.05). After treatment, FPG, 2 h PG, and HbA1c in two groups were significantly decreased (P < 0.05), and FPG, 2 h PG, and HbA1c in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum levels of GSH-Px and TAOC in two groups were higher than those before treatment, but the serum levels of AOPPs in two groups were lower than those before treatment (P < 0.05). The serum levels of GSH-Px and TAOC in the treatment group were higher than those in the control group, but the serum levels of AOPPs in the treatment group were lower than those in the control group, with a statistically significant difference (P < 0.05). Conclusion Mulberry Twig Alkaloids Tablets combined with Dapagliflozin Tablets has clinical curative effect in treatment of type 2 diabetes mellitus, improve the quality of life of patients, significantly reduce the blood sugar level and reduce oxidative stress reaction.
Keywords:Mulberry Twig Alkaloids Tablets  Dapagliflozin Tablets  type 2 diabetes mellitus  DSQL score  FPG  2 h PG  HbA1c  GSH-Px  TAOC  AOPPs
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号